Home › Research › Tau biomarkers
Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease
Yakushev I, Bartenstein P, Siessmeier T, Hiemke C, Scheurich A, Lotz J, Fellgiebel A, Müller MJ.. Dementia and geriatric cognitive disorders, 2010-09-15
Topic: Amyloid, tau and blood-test diagnosis
Aims In this study, we aimed to compare cerebrospinal fluid (CSF) levels of total tau (t-tau), phosphorylated tau (p-tau(181)) and positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) in the differential diagnosis of Alzheimer's disease (AD) under clinical conditions. Method In a cross-sectional, blinded, single-center study, we examined a sample of 75 unselected memory clinic patients with clinical diagnoses of dementia of Alzheimer type (DAT; n = 24), amnestic mild cognitive impairment (MCI; n = 16), other dementias (n = 13) and nondemented controls (n = 22). Discriminative accuracy, sensitivity and specificity were calculated and compared using ROC analyses.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yakushev, I., Bartenstein, P., Siessmeier, T., Hiemke, C., Scheurich, A., Lotz, J., et al. (2010). Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease. Dementia and geriatric cognitive disorders. https://doi.org/10.1159/000320206
Vancouver
Yakushev I, Bartenstein P, Siessmeier T, Hiemke C, Scheurich A, Lotz J, et al. Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease. Dementia and geriatric cognitive disorders. 2010. doi:10.1159/000320206. PMID: 20847555.
BibTeX
@article{yakushev2010-20847555,
author = {Yakushev, I. and Bartenstein, P. and Siessmeier, T. and Hiemke, C. and Scheurich, A. and Lotz, J. and Fellgiebel, A. and Müller, M. J.},
title = {{Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease}},
journal = {Dementia and geriatric cognitive disorders},
year = {2010},
doi = {10.1159/000320206},
pmid = {20847555},
url = {https://doi.org/10.1159/000320206}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Method In a cross-sectional, blinded, single-center study, we examined a sample of 75 unselected memory clinic patients with clinical diagnoses of dementia of Alzheimer type (DAT; n = 24), amnestic mild cognitive impairment (MCI; n = 16), other dementias (n = 13) and nondemented controls (n = 22).
- Discriminative accuracy, sensitivity and specificity were calculated and compared using ROC analyses.
- Results p-tau(181) and FDG-PET were comparable in separating DAT from controls (sensitivity: 67 vs. 79%; specificity: 91% for both) and patients with other dementias (sensitivity: 71 vs. 79%; specificity: 100% for both).
- The sensitivity of p-tau(181) in differentiating MCI patients from controls was significantly (p Conclusions FDG-PET and CSF p-tau(181) levels are able to discriminate DAT in heterogeneous and unselected samples with a high accuracy.
Why it matters
In 75 memory clinic patients, spinal fluid phosphorylated tau and FDG-PET performed similarly in separating Alzheimer's dementia from controls. This is a diagnostic comparison and does not address treating or curing the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants24
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Dementia and geriatric cognitive disorders) |
| Journal's citation record | 1 / 4 | Dementia and Geriatric Cognitive Disorders: journal h-index 149 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 24 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Matthias Johannes Müller: h-index 32 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Ludwig-Maximilians-Universität München: institution h-index 1,224 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20847555) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1159/000320206
- PubMed: 20847555
- Original source →
- Free full text: Dementia and Geriatric Cognitive Disorders →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Tau biomarkers
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.